The World Health Organization (WHO) operates a prequalification programme to assess the quality, safety and efficacy of products that address global public health priorities. Pre-qualified products are listed on the WHO website as eligible for procurement, giving purchasing agencies such as UNICEF a range of quality-assured diagnostics, medicines and vaccines from which to choose. Charles River Associates was asked to support the development of a new financing arrangement that addressed the needs of all stakeholders, including industry groups, key partners and the WHO.
To read more, click the link below.
Disparities in screening and diagnosis for triple negative breast cancer
Gilead Sciences asked Charles River Associates and Tigerlily Foundation to examine the extent to which policies associated with triple negative breast cancer...